Pfizer's RSV candidate receives FDA special status

The US health authority will accelerate its review of US-based Pfizer’s vaccine against RSV after granting it the Breakthrough Therapy Designation.
Photo: CARLO ALLEGRI/REUTERS / X02452
Photo: CARLO ALLEGRI/REUTERS / X02452
by marketwire, translated by daniel pedersen

Pfizer can look forward to a faster approval process for its vaccine against respiratory syncytial virus (RSV), as the US Food and Drug Administration (FDA) will fast-track its drug review, Bloomberg reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading